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A homozygous SFTPA1 mutation drives necroptosis
of type II alveolar epithelial cells in patients with
idiopathic pulmonary fibrosis
Akio Takezaki1,2, Shin-ichi Tsukumo1,3, Yasuhiro Setoguchi4,5, Julie G. Ledford6, Hisatsugu Goto2, Kazuyoshi Hosomichi7, Hisanori Uehara8,
Yasuhiko Nishioka2,9, and Koji Yasutomo1,3,9
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by scattered fibrotic lesions in the lungs. The pathogenesis
and genetic basis of IPF remain poorly understood. Here, we show that a homozygous missense mutation in SFTPA1 caused IPF
in a consanguineous Japanese family. The mutation in SFTPA1 disturbed the secretion of SFTPA1 protein. Sftpa1 knock-in
(Sftpa1-KI) mice that harbored the same mutation as patients spontaneously developed pulmonary fibrosis that was
accelerated by influenza virus infection. Sftpa1-KI mice showed increased necroptosis of alveolar epithelial type II (AEII) cells
with phosphorylation of IRE1α leading to JNK-mediated up-regulation of Ripk3. The inhibition of JNK ameliorated pulmonary
fibrosis in Sftpa1-KI mice, and overexpression of Ripk3 in Sftpa1-KI mice treated with a JNK inhibitor worsened pulmonary
fibrosis. These findings provide new insight into the mechanisms of IPF in which a mutation in SFTPA1 promotes necroptosis of
AEII cells through JNK-mediated up-regulation of Ripk3, highlighting the necroptosis pathway as a therapeutic target for IPF.
Introduction
Idiopathic pulmonary fibrosis (IPF) is characterized by scattered
fibrotic lesions in the lungs and has a median survival time of
<3 yr (Raghu, 2011; Steele and Schwartz, 2013; Ahluwalia et al.,
2014). The pathogenesis of IPF is poorly understood, and no
effective approaches are available to reverse the development of
pulmonary fibrosis. Previous papers have proposed that IPF is
caused by repeated injury to alveolar epithelial cells, resulting in
excessive and sustained fibroblast activation and subsequent
accumulation of matrix-producing myofibroblasts (Noble et al.,
2012). The environmental and genetic factors underlying spo-
radic IPF are unknown, though cases of familial IPF have been
linked to mutations in telomerase (Armanios, 2013; Steele and
Schwartz, 2013; Putman et al., 2014). A genome-wide linkage
analysis revealed that variants in the promoter region ofMUC5B
were strongly associated with IPF (Seibold et al., 2011). A rare
heterozygous missense mutation in SFTPA2, which encodes
surfactant protein A (SP-A) 2, was also reported; SFTPA2 pro-
teins carrying the mutation were retained in the ER and
therefore not secreted (Wang et al., 2009). SFTPA2 forms a
complex with SFTPA1, which is secreted into the alveolar space
as SP-A (Maitra et al., 2010). A heterozygous missense mutation
in SFTPA1 was also found in IPF patients (Nathan et al., 2016).
However, it remains unclear how the mutations in SFTPA1 or
SFTPA2 are associated with the pathogenesis of IPF.
Necroptosis is thought to be a pro-inflammatory type of
cell death that releases intracellular contents that stimulate
immune cells (Galluzzi and Kroemer, 2008; Pasparakis and
Vandenabeele, 2015; Silke et al., 2015). The necroptosis ma-
chinery comprises receptor interacting serine/threonine ki-
nase 3 (RIPK3) and pseudokinase mixed lineage kinase-like
(MLKL). RIPK3 is activated through TNF receptor families,
TLR3, TLR4, or DNA sensor (He et al., 2011; Li et al., 2012;
Vanden Berghe et al., 2014). Autophosphorylated RIPK3
phosphorylates MLKL, which drives its oligomerization and
translocation to membranes (Sun et al., 2012; Rickard et al.,
2014). Although necroptosis is known to contribute to several
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types of pathological injury and inflammation (Moriwaki and
Chan, 2013; Pasparakis and Vandenabeele, 2015; Silke et al.,
2015), the contribution of necroptosis to human diseases is
unclear.
Recent advances in exome resequencing have helped
identify various disease-causing genes in inherited diseases
even in single family or two families (Kitamura et al., 2011,
2014). Here, we describe the identification of a homozygous
missense mutation in SFTPA1 in patients of a consanguineous
Japanese family. The homozygous missense mutation led to
the failure of SP-A secretion. Mice that harbored the same
mutation in Sftpa1 (Sftpa1 knock-in [Sftpa1-KI] mice) devel-
oped an IPF-like disease that was accelerated by influenza
virus infection, leading to increased death of alveolar epi-
thelial type II (AEII) cells. The deletion of Ripk3 or Mlkl from
Sftpa1-KI mice ameliorated the pulmonary fibrosis, indicat-
ing that necroptosis is involved in cell death. We also found
that increased phosphorylation of IRE1α (a component of ER
stress responses) led to phosphorylation of JNK in AEII cells
in Sftpa1-KI mice, which up-regulated Ripk3. The inhibition
of IRE1α or JNK ameliorated pulmonary fibrosis in Sftpa1-KI
mice. In addition, overexpression of Ripk3 in JNK inhibitor-
treated Sftpa1-KI mice exacerbated pulmonary fibrosis. These
findings provide new insights into the mechanisms of IPF by
suggesting that the enhancement of necroptosis is crucial for
pulmonary fibrosis. We highlight the necroptosis pathway as
a future therapeutic target for IPF.
Results and discussion
Patient history and genetic analysis
In a single Japanese family with consanguineous marriage,
two of the sons were diagnosed with IPF at the ages of 24 and
27 yr and died at 32 and 34 yr, respectively (Fig. S1 a; Yoshioka
et al., 2004). The youngest brother also began to develop
dyspnea at the age of 40 yr. These patients were diagnosed
using the criteria outlined in the official American Thoracic
Society/Euroean Respiratory Society/Japanese Respiratory
Society/Latin American Thoracic Association clinical practice
guidelines (Raghu et al., 2018). Given the consanguinity of the
family, an autosomal-recessive disease-causing variant was
suspected. The parents of the patients do not show any clinical
signs of pulmonary fibrosis, although they were not evaluated
by computed tomography analysis. We performed homozy-
gosity mapping, linkage analysis, and exome resequencing to
find 15 shared rare variants between the two older brothers.
Among those 15 rare variants, we found a homozygous mis-
sense mutation in SFTPA1 (T622C) located in the homozygous
region shared by the two older brothers (Fig. S1 b). This
variant is not present in several human genetic variation
databases, including the 1000 Genomes Project and the Exome
Aggregation Consortium. The variant showed co-segregation
with the disease under the assumption of autosomal-recessive
inheritance, with both parents being heterozygous for the
detected variant. This mutation changed the amino acid at
position 208 from tyrosine to histidine (Fig. S1 b) and is lo-
cated in the carbohydrate recognition domain (Fig. S1 b).
A mutation in SFTPA1 disrupts the secretion of SFTPA1
To evaluate the effect of this SFTPA1mutation on its expression,
secretion of SFTPA1 protein, or complex formation with
SFTPA2, WT Flag tagged-SFTPA1 (Fig. S1 c), or SFTPA2 (Fig. S1
d), was co-transfected with myc-tagged WT or mutant SFTPA1,
and their association in the cell pellet or supernatant was
evaluated by immunoprecipitation with an anti-Flag antibody
and blotting with an anti-myc antibody (Fig. S1, c and d). The
WT SFTPA1 protein complexed with SFTPA1 (Fig. S1 c) or
SFTPA2 (Fig. S1 d) in the cell pellets and supernatants as pre-
viously reported (Maitra et al., 2010). The mutant SFTPA1
protein complexed with SFTPA2 in cell pellets. However, mu-
tant SFTPA1–WT SFTPA1 or mutant SFTPA1–WT SFTPA2
complexes were scarcely detected in the supernatants (Fig. S1, c
and d). These data suggest that the mutation in SFTPA1 disrupts
the secretion of SFTPA1.
Mice carrying the mutation in SFTPA1 spontaneously
developed pulmonary fibrosis
To determine if the SFTPA1 mutation in in this family contrib-
uted to IPF development, we created mice (Sftpa1-KI) that car-
ried the samemutation in themouse gene Sftpa1 (Y208H; Fig. S2 a).
The homologous recombination of the construct harboring the
mutant Sftpa1 was confirmed by Southern blotting (Fig. S2 a).
Mice born with normal Mendelian frequency showed growth
rates similar to WT and did not show any differences in the
frequencies of immune cells, including T cells, B cells, mac-
rophages, and dendritic cells in the spleen and lymph nodes
(data not shown).
We next evaluated the secretion of Sftpa1 in Sftpa1-KI mice.
The bronchoalveolar lavage (BAL) fluid from Sftpa1-KI mice
did not contain SFTPA1 (Fig. 1 a). In contrast, in WT mice, high
production of SFTPA1 was found in BAL fluid (Fig. 1 a). The
lung tissue samples in Sftpa1-KI mice expressed equivalent
levels of SFTPA1 (Fig. 1 a). These findings were in line with the
impaired secretion of mutant human SFTPA1 in transfected
A549 cells.
The Sftpa1-KI mice were healthy at ages 8–30 wk but began
to die around 40 wk of age (Fig. 1 b). The lung sections of Sftpa1-
KI mice showed increased cell infiltration and fibrotic regions at
the age of 35 wk (Fig. 1 c). These pathological changes were not
detected at 20 wk of age in Sftpa1-KI mice but were evident at 35
wk of age (Fig. 1 c). We evaluated type 1 collagen mRNA (Col1a1;
Fig. 1 d) and hydroxyproline (Fig. 1 e) at the ages of 10, 20, and 30
wk. We began to detect increased Col1a1 mRNA and hydroxy-
proline at the ages of 20 and 30 wk, respectively. The arterial
PaO2 levels of Sftpa1-KI mice at 10 and 20 wk of age were
equivalent to those of WT mice. The PaO2 levels began to de-
crease at the age of 30wk and dropped further at 35 wk (Fig. 1 f).
Similar pulmonary fibrosis was also observed in mice in which
the point mutation was inserted using the CRISPR-Cas9 method
(Fig. S2 b). These data demonstrated that the Sftpa1 mutation in
mice caused spontaneous pulmonary fibrosis at 20 wk of age
with further deterioration with aging. This finding strongly
suggested that the corresponding mutation in human SFTPA1
found in the study family was the causative mutation for IPF in
these cases.
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Influenza virus infection accelerated pulmonary fibrosis in
Sftpa1-KI mice
To evaluate the molecular mechanism underlying pulmonary
fibrosis in Sftpa1-KI mice, we infected them with influenza A
virus (IAV) because lung infection is known to worsen clinical
symptoms in IPF patients (Moua et al., 2016). Both control and
Sftpa1-KI mice at the age of 20 wk showed similar virus titers in
the lungs 3–12 d after IAV infection (Fig. S2 c). The virus was
eradicated 12 d after infection (Fig. S2 c). This demonstrated that
the Sftpa1mutation did not affect susceptibility to IAV infection.
However, Sftpa1-KI mice began to die 13 d after infection, and by
28 d, ∼70% of the mice had died (Fig. 2 a). The control and
Sftpa1-KI mice had similar total cell numbers 3 and 7 d after
infection (Fig. 2 b). The lung histopathology of IAV-infected
Sftpa1-KI mice showed pulmonary fibrosis with cellular
infiltration 10 d after infection with high pathological score,
whereas the control lungs showed little sign of pulmonary fi-
brosis (Fig. 2 c). Lung hydroxyproline was higher in Sftpa1-KI
mice than in control mice (Fig. 2 d). In addition, the level of
matrix metalloproteinase-9 in the BAL fluid was increased in
aged Sftpa1-KI mice as well as in IAV-infected Sftpa1-KI mice
(Fig. 2 e).
Influenza virus infection accelerated pulmonary fibrosis in
Sftpa1-KI mice
As epithelial cell death is involved in pulmonary fibrosis (Farkas
et al., 2011), we tested for the death of AEII cells in Sftpa1-KI
mice. In Sftpa1-KI mice, more AEII cells were positive for
7-aminoactinomycin D (7AAD) after infection with IAV. This
was more evident at 30 wk of age than 10 wk of age (Fig. 3 a).
Figure 1. Sftpa1-KI mice spontaneously developed pulmonary fibrosis. (a) Western blot analysis of Sftpa1 in lung tissue or BAL fluid of WT or Sftpa1-KI
mice. (b) Survival analysis of WT (closed squares) or Sftpa1-KI mice (open circles; number of mice in each independent experiment is 20). **, P < 0.01 by log-
rank test. (c) Representative image of Masson’s trichrome-staining (4× for WT and Sftpa1-KI [the scale bar indicates 200 μm] and 40× for Sftpa1-KI mice [the
scale bar indicates 20 μm]) of lung sections from WT or Sftpa1-KI mice at the age of 35 wk and their pathological score. Data are means ± SD. **, P < 0.01.
(d and e) Quantification of mRNA of Co11a1 (d) and hydroxyproline contents (e) in WT or Sftpa1-KI mice (number of mice in each independent experiment is
seven) at the indicated age. (f) Measurement of arterial PaO2 in WT or Sftpa1-KI mice (number of mice in each independent experiment is seven) at the
indicated age. Data (d–f) are means ± SD. *, P < 0.05; **, P < 0.01. Data shown are representative of four (b–e) independent experiments or cumulative of three
(f) independent experiments.
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The number of SP-C–positive cells was also lower in Sftpa1-KI
than WT mice at the age of 30 wk (Fig. 3 a). These data indicate
that AEII cells in Sftpa1-KI mice have a tendency to die compared
with those inWTmice. The expression of active caspase-3 in the
AEII cells of Sftpa1-KI mice was equivalent to the WT (Fig. 3 b),
suggesting that apoptosis was not involved in the increased cell
death in Sftpa1-KI mice. We next sought to assess the contri-
bution of necroptosis to cell death. We crossed Sftpa1-KI mice
with Ripk3-deficient (Sftpa1-KI; Ripk3−/−) mice and infected the
resultant offspring with IAV. About 90% of the Sftpa1-KI;
Ripk3−/− mice survived after IAV infection, although >60% of
control Sftpa1-KI mice died after infection (Fig. 3 c). The accu-
mulation of hydroxyproline was also less in Sftpa1-KI; Ripk3−/−
mice than in control mice (Fig. 3 c). In Sftpa1-KI; Ripk3−/− mice,
the number of AEII cells positive for 7AAD after infection with
IAV was equivalent to the WT (Fig. 3 d). The Sftpa1-KI; Ripk3−/−
Figure 2. Infection with IAV accelerated the
development of pulmonary fibrosis in Sftpa1-
KI mice. (a) Survival analysis of WT (closed cir-
cles) or Sftpa1-KI (red squares) mice at the age of
20 wk after IAV infection (number of mice in
each independent experiment is 10). **, P < 0.01
by log-rank test. (b) Total cell number in BAL
fluid was counted inWT or Sftpa1-KI mice (n = 10
each) 3 (blue) or 7 (orange) d after IAV infection.
Data are means ± SD. **, P < 0.01. (c) Repre-
sentative image of Masson’s trichrome-staining
of lung sections and clinical score from WT or
Sftpa1-KI mice 10 d after IAV infection. The scale
bar indicates 200 μm. Data are means ± SD. **,
P < 0.01. (d) Quantification of hydroxyproline
contents in WT or Sftpa1-KI mice (number of
mice in each independent experiment is 10) 10 d
after IAV infection. Data are means ± SD. *, P <
0.05. (e) Matrix metalloprotease-9 levels in the
BAL fluid in WT and Sftpa1-KI mice at the age of
14 or 35 wk or in IAV-infected WT and Sftpa1-KI
mice at the age of 20 wk (day 10; **, P < 0.01;
number of mice in each independent experiment
is five). Data shown are representative of five
(a–c) independent experiments or cumulative of
two (d and e) independent experiments.
Takezaki et al. Journal of Experimental Medicine 4
A mutation in SFTPA1 and pulmonary fibrosis https://doi.org/10.1084/jem.20182351
Takezaki et al. Journal of Experimental Medicine 5
A mutation in SFTPA1 and pulmonary fibrosis https://doi.org/10.1084/jem.20182351
mice did not die during the first 56 wk of life (Fig. 3 e). The
deletion of Ripk3 led to the reduction of hydroxyproline accu-
mulation and recovered PaO2 level in Sftpa1-KI mice (Fig. 3 e).
Moreover, deletion of Mlkl in Sftpa1-KI mice also showed re-
sistance to pulmonary fibrosis after IAV infection (Fig. S2 d).
These data suggest that increased necroptosis was responsible
for Sftpa1-KI mouse death.
To assess whether necroptosis was enhanced in IPF patients
with SFTPA1 mutations, we evaluated a patient’s expression of
phosphorylated MLKL. Although we could assess a lung speci-
men from only one patient, we detected increased levels of
phosphorylated MLKL expression in AEII cells of the IPF patient
(Fig. S2 e). Phosphorylated MLKL was not detected in control
lung tissue and other IPF patients without SFTPA1mutation (Fig.
S2 e).
Increased ER stress and JNK activation contributed to IPF
As the secretion but not intracellular expression of Sftpa1 was
disturbed in Sftpa1-KI mice, we sought to determine whether ER
stress was induced in Sftpa1-KI mice. We tested the phospho-
rylation of IRE1α in AEII cells from control and Sftpa1-KI mice
infected with IAV. The infected AEII cells from Sftpa1-KI mice
showed increased phosphorylation of IRE1α compared with WT
mice 10 d after infection (Fig. 4 a). However, we did not find
differences in phosphorylated elF2α expression (Fig. S3 a).
Up-regulated phosphorylation of IRE1α was detected even in
uninfected Sftpa1-KI mice at the age of 20 wk (Fig. 4 a). The
phosphorylation of IRE1α activates and phosphorylates JNK
(Sano and Reed, 2013). Therefore, we measured phosphorylated
JNK levels in AEII cells from Sftpa1-KI mice infected with IAV
(Fig. 4 b). The AEII cells from Sftpa1-KI mice showed increased
phosphorylation of JNK (Fig. 4 b and Fig. S3 b), and its phos-
phorylation was suppressed by blockade of IRE1α (Fig. 4 b). The
increased phosphorylation of JNK was detected in AEII cells in
Sftpa1-KI mice infected with IAV (Fig. S3 c). To determine
whether JNK activation was involved in lung fibrosis in Sftpa1-
KI mice, we treated Sftpa1-KI mice with a JNK inhibitor. The JNK
inhibitor ameliorated lung fibrosis in Sftpa1-KI mice, although
less efficiently than deleting the Ripk3 gene (Fig. 4 c).
To evaluate the association of the IRE1α-JNK pathway with
necroptosis, we evaluated the expression of Ripk3 in AEII cells.
We detected increased expression of Ripk3 in Sftpa1-KI com-
pared with WT mice infected with IAV (Fig. 4 d). Treatment
with a JNK inhibitor reduced Ripk3 expression in Sftpa1-KI mice
(Fig. 4 d), indicating that Ripk3 expression is regulated by JNK
activation. This dose of JNK inhibitor clearly suppressed LPS-
induced TNF-α production in mice (Fig. S3 d). In addition, even
in the absence of IAV infection, Ripk3 expression was higher in
Sftpa1-KI than WT mice at the age of 20 wk (Fig. 4 d). In addi-
tion, although we tried to detect phosphorylatedMLKL (pMLKL)
and IRE1α in situ, we have not been able to detect any specific
staining of eachmolecule in situ by using commercially available
antibodies.
Increased Ripk3 expression contributes to IPF
Finally, we analyzed whether increased Ripk3 expression in-
duced by JNK activation was responsible for pulmonary fibrosis
in Sftpa1-KI mice. We constructed an adenovirus vector encod-
ing Ripk3 (Ripk3-adenovirus). The intratracheal infection of
Ripk3-adenovirus in WT mice led to overexpression of Ripk3-
adenovirus in the lung (Fig. 5 a). The infection of Ripk3-
adenovirus reduced the survival of Sftpa1-KI mice that were
infected with IAV and treated with a JNK inhibitor (Fig. 5 b and
Fig. S3 e), demonstrating that JNK-mediated Ripk3 expression is,
at least partly, responsible for the pulmonary fibrosis in Sftpa1-
KI mice. The overexpression of Ripk3 in WT mice infected with
IAV also showed pulmonary fibrosis, although it was less than in
Sftpa1-KI mice infected with IAV.
Here, we identified a homozygous mutation in SFTPA1 in IPF
patients from a consanguineous Japanese family. We demon-
strated that mice carrying the same mutation in Sftpa1 sponta-
neously developed pulmonary fibrosis that was accelerated by
IAV infection. ER stress was induced in AEII cells in Sftpa1-KI
mice, resulting in activation of the JNK-Ripk3 pathway. Previous
studies have reported the presence of highly activated JNK in
IPF- and bleomycin-instilled lung tissue samples, and over-
expression of caveolin-1 was able to suppress JNK (Wang et al.,
2006). JNK signaling in AEII cells up-regulated Ripk3 expres-
sion, leading to an increased sensitivity to necroptosis in AEII
cells, which contributed to the development of pulmonary fi-
brosis. These studies identified necroptosis of AEII cells as the
crucial event in pulmonary fibrosis, illustrating the potential
utility of targeting necroptosis in the treatment of IPF.
Earlier studies in IPF patients demonstrated epithelial cell
loss and increased epithelial cell death, including apoptosis and
necrosis (Uhal et al., 1998; Tanjore et al., 2012). Subsequent
Figure 3. Increased necroptosis of AEII cells in Sftpa1-KI mice. (a) The percentage of 7AAD-positive cells (at the ages of 10 or 30 wk) in AEII cells or
SP-C–positive cells (average of the number of SP-C–positive cells in 10 independent fields in right lung) was counted (number of mice in each independent
experiment is 10). Data are means ± SD. n.s., not significant; **, P < 0.01. (b) The expression of active caspase-3 (at the age of 30 wk) from WT or Sftpa1-KI
mice 10 d after IAV infection. As a negative control, unstained sample was prepared, and isotype-matched antibodies were used to stain WT cells (control). The
number in each figure indicates the percentage of active caspase-3–positive cells. Data are means ± SD. (c) Survival of WT (closed circles), Ripk3−/− (open
circles), Sftpa1-KI (red squares), or Sftpa1-KI; Ripk3−/− (closed squares) mice after IAV infection (number of mice in each independent experiment is 10). **, P <
0.01 by log-rank test. Quantification of hydroxyproline contents in control, Ripk3−/−, Sftpa1-KI, or Sftpa1-KI; Ripk3−/−mice (number of mice in each independent
experiment is 10) 12 d after IAV infection. Data represent the means ± SD. **, P < 0.01. (d) The percentage of 7AAD-positive cells in AEII cells fromWT, Sftpa1-
KI, or Sftpa1-KI; Ripk3−/−mice 10 d after IAV infection. Data are means ± SD. **, P < 0.01. (e) Survival of WT (closed squares), Sftpa1-KI (open circles), or Sftpa1-
KI; Ripk3−/− (open triangles) mice after IAV infection (number of mice in each independent experiment is 20). **, P < 0.01 by log-rank test. Quantification of
hydroxyproline contents or measurement of arterial PaO2 in WT, Sftpa1-KI, or Sftpa1-KI; Ripk3−/− mice (number of mice in each independent experiment is
seven) at the indicated age. Data are means ± SD. *, P < 0.05; **, P < 0.01. The data in this figure are representative of four independent experiments. Data
shown are representative of five (c–e) independent experiments or cumulative of five (a and b) independent experiments.
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Figure 4. Enhanced ER stress in AEII cells from Sfpta1-KI mice. (a)Western blot showing levels of phosphorylated IRE1α and actin in AEII cells of 20-wk-old
WT and Sftpa1-KI (KI) mice 7 d after infection with IAV or uninfected WT and KI mice at 20 wk of age. Data represent the means ± SD. *, P < 0.05; **, P < 0.01.
(b) Flow cytometric analysis of phosphorylated JNK in WTmice, day 7 IAV-infected Sftpa1-KI or WT mice, or Sftpa1-KI mice infected with IAV and treated with
IRE1α inhibitor. Data represent the means ± SD. **, P < 0.01. (c) Survival of WT (closed squares), Sftpa1-KI (open circles), or Sftpa1-KI (closed circles) mice at
the age of 20 wk treated with a JNK inhibitor after IAV infection (number of mice in each independent experiment is 10). *, P < 0.05 by log-rank test.
Quantification of hydroxyproline contents in WT or Sftpa1-KI mice (number of mice in each independent experiment is 10) 12 d after IAV infection. Data
represent the means ± SD. *, P < 0.05. (d) RIPK3 expression in AEII cells in 20-wk-old WT and Sftpa1-KI mice, 20-wk-old WT and Sftpa1-KI mice 7 d after
infection with IAV, and 20-wk-old KI mice 7 d after infection with IAV and treated with a JNK inhibitor. Data represent the means ± SD. **, P < 0.01. Data shown
are representative of five (c and d) independent experiments or cumulative of five (a and b) independent experiments.
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studies suggested that repeated epithelial injury led to a highly
aberrant wound healing response that contributed to IPF path-
ogenesis (Datta et al., 2011). Indeed, increased TUNEL or cleaved
caspase-3–positive cells in lung tissue from IPF patients sug-
gested the involvement of apoptosis in IPF pathogenesis (Korfei
et al., 2008). The most widely used animal model for IPF is
bleomycin-induced pulmonary fibrosis, which is caused by in-
jury and cell death of alveolar epithelial cells. A caspase inhibitor
can ameliorate bleomycin-induced pulmonary fibrosis (Kuwano
et al., 2001), suggesting that apoptosis is involved in pulmonary
fibrosis in this model. However, it remains unclear if apoptosis
or necrosis is directly involved in the onset or progression of
human IPF. Our current data demonstrate that necroptosis is the
crucial cell death pathway that causes IPF in the family reported
here and potentially in others with a similar mutation. This is
supported by the deletion of Ripk3 or Mlkl that could suppress
the development of IPF in Sftpa1-KI mice, although we need to
establish a more refined system, such as the deletion of either
gene in only AEII cells, to more fully confirm this hypothesis in
future studies. Necroptosis acts as a mediator for pathogen de-
fense and inflammation (Pasparakis and Vandenabeele, 2015).
Unlike apoptosis, which is considered to be nonimmunogenic,
dying cells that undergo necrosis or necroptosis release damage-
associated molecular patterns believed to trigger inflammation.
There are several studies that implicate necroptosis in tissue
inflammation in animal models (Bonnet et al., 2011; Welz et al.,
2011; Wu et al., 2013). However, there is no evidence that nec-
roptosis is directly involved in human diseases. In this regard,
our study is the first to establish a link between necroptosis and
inherited IPF and paves the way for future work to examine the
contribution of necroptosis to human inflammatory diseases.
Although the subsequent molecular cascades or cellular inter-
actions after necroptosis of AEII cells have yet to be determined,
our study suggests that blocking necroptosis in AEII cells should
suppress the very early events that lead to pulmonary fibrosis in
IPF patients.
The activation of RIPK1 leads to cell death through the for-
mation of a RIPK1–TRADD–FADD–caspase-8 complex (Shan
et al., 2018; Yuan et al., 2019). This complex triggers caspase
activation and causes RIPK1-dependent apoptosis. When caspase
activity is deficient in this situation, RIPK1 activation leads to
necroptosis through the formation of a RIPK1–RIPK3–MLKL
complex in which phosphorylation of MLKL by RIPK3 leads to
disruption of the cell membrane and cell lysis (Yuan et al., 2019).
Moreover, RIPK3 regulates not only necroptosis but also other
cellular responses independent of MLKL. For instance, RIPK3
regulates kidney fibrosis via AKT-dependent ATP citrate lyase
(Imamura et al., 2018). In the present study, although we did
not evaluate the roles of RIPK1, deletion of Ripk3 or Mlkl sup-
pressed the progression of pulmonary fibrosis in Sftpa1-KI mice,
Figure 5. Up-regulation of Ripk3 contributed to IPF development in Sftpa1-KI mice. (a) Western blot analysis of the levels of Ripk3 and β-actin in WT
mice infected with control adenovirus or adenovirus carrying Ripk3. (b) Survival of 20-wk-old WT (red circles), WT infected with adenovirus carrying Ripk3
(yellow squares), Sftpa1-KI mice infected with control virus (blue circles), Sftpa1-KI mice infected with control virus and treated with a JNK inhibitor (brown
triangles), or Sftpa1-KI mice infected with adenovirus carrying Ripk3 and treated with a JNK inhibitor (green squares; number of mice in each independent
experiment is 10). *, P < 0.05; **, P < 0.01 by log-rank test. Quantification of hydroxyproline contents in WT or Sftpa1-KI mice (number of mice in each
independent experiment is 10) 12 d after IAV infection. Data represent the means ± SD. *, P < 0.05; **, P < 0.01 by multiple testing corrections. Data shown are
representative of three (b) independent experiments.
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demonstrating that RIPK3-mediated MLKL activation is a crucial
determinant for pulmonary fibrosis in Sftpa1-KI mice. The
question remains as to which upstream pathways activate RIPK3
in Sftpa1-KI mice. The overexpression of RIPK3 in WT mice in-
fected with IAV showed pulmonary fibrosis, although less so than
Sftap1-KImice, which suggests that high expression of RIPK3may
be a key determinant in the increased susceptibility for nec-
roptosis in AEII cells. The improved survival inWTmice inwhich
RIPK3 is overexpressed compared with Sftpa1-KI mice infected
with IAV could be attributed to the presence of key upstream
factors that trigger RIPK3 in Sftap1-KI mice, the presence of
RIPK3-independent pathways to increase the susceptibility to
necroptosis in Sftpa1-KI mice, or the incomplete adenoviral
mediated-overexpression of RIPK3 in all parts of the lung.
Our data demonstrate that necroptosis is one of the crucial
initiators of pulmonary fibrosis. Therefore, the signaling path-
way of necroptosis could be a potential target for its treatment.
The current focus for treating IPF is to block the activation of
kinases in fibrotic regions involved in IPF progression (Richeldi
et al., 2011, 2014; King et al., 2014). In contrast, the modulation of
necroptosis in AEII cells would suppress earlier events in IPF
progression, which would be more beneficial to patients. Our
data thus provide not only a new link between necroptosis and
IPF, but also a novel strategy for treating patients with IPF.
Materials and methods
Patients and ethics
All genetic studies were conducted after obtaining informed
consent from the patients or the patients’ relatives (if patients
were deceased). The studies were approved by the human ge-
nome research and clinical studies ethics committee of To-
kushima University. This study was conducted in accordance
with the principles of the Declaration of Helsinki.
Exome resequencing and DNA sequencing
Exome sequencing and data analysis were performed as de-
scribed previously (Kitamura et al., 2011, 2014). Briefly, a paired-
end library was prepared from genomic DNA and hybridized to
biotinylated complementary RNA oligonucleotide baits from the
SureSelect Human All Exon Kit (Agilent Technologies). The li-
brary was sequenced with paired-end, 75-bp reads on one lane of
an Illumina Hiseq 1500 sequencing system. The sequence reads
were aligned to the human reference sequence of the UCSC Ge-
nome Browser (hg19). 90% of the entire targeted exome was
covered by >10 reads. DNA variants located in the candidate re-
gion were filtered against the databases of the Single Nucleotide
PolymorphismDatabase build 134, the 1000 Genomes Project, and
the National Heart, Lung, and Blood Institute Exome Sequencing
Project. Missense, nonsense, frameshift, and splice-site alleles
were evaluated. The mutation in SFTPA1 was sequenced using an
ABI Prism 3100 genetic analyzer (PE Applied Biosystems).
Single nucleotide polymorphism homozygosity mapping and
linkage analysis
Both affected and unaffected siblings from one consanguineous
family were studied with the Illumina Human 610 Quad Bead
Chip. Sample processing and labeling were performed in ac-
cordance with the manufacturer’s instructions. An average call
rate of >99% was obtained. Homozygous regions were identified
using HomozygosityMapper (Seelow et al., 2009). Our labora-
tory has developed a graphic interface that allows an easy
comparison of common homozygous regions between three
patients from different families. For linkage analysis, multi-
point log of the odds ratio scores were obtained using Merlin
software (Abecasis et al., 2002).
Mice
C57BL/6 mice were purchased from Japan SLC. Sftpa1-KI mice
were established by constructing a targeting vector with a mu-
tation in Sftpa1 or putting a mutation in Sftpa1 in the CRISPR/
Cas9 method. All mice, including Ripk3−/−, Mlkl−/−, and Sftpa1-
KI mice, were maintained in the animal research center of To-
kushima University, and all animal experiments were approved
by the animal research committee of Tokushima University and
performed in accordance with our institution’s guidelines for
animal care and use.
BAL
Mice were euthanized, and lung tissue and BAL fluids were
collected using 0.8-ml aliquots of PBS. Cell-free BAL fluids were
stored in a −80°C freezer before analysis.
Flow cytometry
Cells were resuspended in staining buffer, incubatedwith anti-FcγRII/
III mAbs (2.4G2) before staining. AEII cells were characterized as
granular cells with high side scatter that expressed Ep-CAM
(anti-CD326 mAb, clone G8.8; BioLegend) and were negative
for CD45, CD11b, CD11c, CD31, and podoplanin. Phosphorylated
JNK was stained with anti–phosphorylated JNK (pJNK) anti-
body (N9-66; BD Biosciences). Active caspase was stained with
Caspase-3 Assay Kit, PhiPhiLux-G2D2. The fluorescence in-
tensity of 105 cells was measured with a FACSCanto II flow
cytometer (BD Biosciences) and analyzed with FACSDiva (BD
Biosciences) software.
Western blotting and immunoprecipitation
Cell pellets were lysed in cold radioimmunoprecipitation assay
buffer (Wako Pure Chemical Industries) and protease inhibitor
(Roche), and the lysates were boiled in SDS loading dye. The
samples were resolved by SDS-PAGE, and the blots were incu-
bated with anti-Flag (F1804; Sigma-Aldrich), anti-Myc (9E10;
Santa Cruz), anti-phospho-IRE1α (rabbit polyclonal antibody;
Novus Biologicals), anti-JNK (#9252; Cell Signaling Technology),
anti-pJNK (#9251; Cell Signaling Technology), anti-phosphory-
lated-eIF2α (#9721; Cell Signaling Technology), eIF2α (#5324;
Cell Signaling Technology), or anti-Ripk3 (rabbit polyclonal
antibody, NBP1-77299; Novus Biologicals) antibodies. They were
next incubated with peroxidase-conjugated goat anti-mouse IgG
(31430; Pierce Biotechnology) or goat anti-rabbit IgG (170–6515;
Bio-Rad) antibodies. As a control, membranes were probed
with polyclonal anti-actin (A2066; Sigma-Aldrich) and HRP-
conjugated goat anti-rabbit IgG antibodies (170–6515; Bio-Rad).
The bands were detected with ECL Prime Chemiluminescent
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Substrate (GE Healthcare) and with the ImageQuant LAS-4000
mini system (GE Healthcare).
For immunoprecipitation analysis, FLAG or Myc-tagged hu-
man SFPTA1 or SFTPA2 cDNAs were cloned in pcDNA and
transfected into A549 cells with GeneJuice (Merck). One day
after transfection, the cells were washed three times with
serum-free medium and then incubated in serum-free medium
for 1 d. The supernatant was subjected to immunoprecipitation
with anti-FLAG antibody clone M2 (Sigma-Aldrich) and Dyna-
beads Protein G (Thermo Fisher Scientific). The cells were
washed with PBS, lysed in RIPA buffer (Wako) and subjected to
immunoprecipitation in the same manner as the supernatant.
The immunoprecipitated samples and total cell lysates were
analyzed by Western blotting with anti-FLAG antibody (clone
M2) or anti-Myc antibody (clone D84C12).
Measurement of matrix metalloprotease-9 levels
The concentration of matrix metalloprotease in BAL fluid from
mice was measured with an MMP-9 activity kit (Quickzyme
Biosciences).
Real-time PCR
Total RNA was isolated (ReliaPrep RNA Cell Miniprep System;
Promega), and cDNA was synthesized (0.1 μg of RNA). Relative
expression was calculated using the comparative threshold cycle
method. PCR analyseswere performed using StepOnePlus (Applied
Biosystems) with primers. Primer sequences are available upon
request. The mRNA level of CypA was used as an internal control.
Purification of AEII
The lungs were perfused with 5 ml of PBS through the pulmo-
nary artery via the right ventricle. 1 ml of porcine elastase (4.5 U;
Roche Diagnostics) was instilled through a tracheal cannula. The
lung lobes were gently separated from the bronchi and minced
in RPMI 1640 medium containing 20% FBS and 100 U/ml DNase I
(Qiagen). Cells in suspension were subsequently filtered through
100-, 70-, and 40-μm nylon mesh (Corti et al., 1996). Contami-
nating leukocytes, endothelial cells, and alveolar type I epithelial
cells were depleted using biotinylated anti-CD45, CD11b, CD11c,
CD31, and podoplanin antibodies (BioLegend) and streptavidin
paramagnetic microbeads (Miltenyi Biotec; Marsh et al., 2009).
Measurement of hydroxyproline
Hydroxyproline concentrations in lung tissues were measured
with a hydroxyproline assay kit (QuickZyme Hydroxyproline
Assay; QuickZyme Biosciences). Hydroxyproline content is ex-
pressed as “μg per lung,” unless specified otherwise.
Histology
Paraffin-embedded sections were used for hematoxylin and eosin
or Masson’s trichrome staining. Lung sections were stained with
hematoxylin and anti-phosphorylated-MLKL (ab187091; Abcam),
anti-pJNK (#9251; Cell Signaling Technology), or SP-C (ab90716;
Abcam) antibody followed by EnVision Dual Link System-HRP
(K4061; Dako), and then visualized with SignalStain DAB Sub-
strate Kit (Cell Signaling Technology). The severity of inflamma-
tion and fibrosis was semi-quantitatively assessed according to the
methods proposed by Genovese et al. (2005) and Ashcroft et al.
(1988). The pathological grade was determined according to the
following criteria: 0, normal; 1, presence of inflammation and fi-
brosis involving <5% of the lung parenchyma; 2, presence of in-
flammation and fibrosis involving <25% of the lung parenchyma; 3,
lesions involving 25–50% of the lung, moderate thickening of the
bronchial wall without obvious damage to lung architecture, or
small fibrousmasses; 4, lesions involving >50% of the lung, definite
damage to lung structure, and formation of fibrous bands or small
fibrous masses; and 5, lesions involving >50% of the lung, severe
distortion of structure, and fibrous obliteration of fields.
Influenza infection
Mice (20 wk old) were anesthetized and inoculated intranasally
with influenza virus (H3N2; Kashima et al., 2009) in 20 μl sterile
PBS. The titer was measured as described previously (Kashima
et al., 2009). The survival of infectedmicewas observed daily. In
other experiments, mice were intravenously treated with a JNK
inhibitor (SP600125; Cell Signaling Technology; 30 mg/kg, s.c.;
day 0: infection; days 5, 7, 9, and 11), or treated with IRE1α in-
hibitor (KIRA6; Thermo Fisher Scientific; 10 mg/kg, intra-
tracheally; day 0: infection; days 3, 5, 7, and 9).
Pulmonary function measurements
The i-STAT Portable Clinical Analyzer and the i-STAT G7+ car-
tridge were used to measure arterial blood gas (Abbott Point of
Care). The arterial blood sampled from the left ventricle of the
mice was introduced into the sample well of the cartridge that
was subsequently inserted into the analyzer. The PaO2 was
measured after completion of the calibration.
Adenovirus infection
The recombinant E1-deleted adenoviral vectors carrying mouse
Ripk3 under cytomegalovirus promoters were generated and
purified. Mice were infected with the recombinant adenovirus
by intratracheally injecting 109 PFU/mouse 1 d after IAV infec-
tion as previously described (Nakao et al., 1999).
Statistics
The statistical significance of between-group differences was
evaluated by an unpaired test, a two-tailed t test, a parametric
Dunnett’s test, or a log-rank test. A P value < 0.05 was consid-
ered significant.
Online supplemental material
Fig. S1 shows the genetic analysis of IPF patients and the effect of
the mutation in SFTPA1 on its protein function. Fig. S2 shows the
development of pulmonary fibrosis in Sftpa1-KI mice. This re-
lates to Figs. 1, 2, and 3. Fig. S3 shows the contribution of the JNK
pathway in the development of pulmonary fibrosis in Sftpa-KI
mice. This relates to Figs. 4 and 5.
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Figure S1. Identification of an SFTPA1 mutation in IPF patients and its effect on the secretion of SFTPA1. (a) Pedigree of a Japanese IPF family: double
lines indicate consanguinity, filled black indicates IPF patients, and diagonal lines indicate deceased siblings. P, patient. (b) The heterozygous (parents) or
homozygous (patients) missense mutation in SFTPA1 (Y208H) as shown by capillary sequencing. SFTPA1 protein domains: the red arrowhead indicates position
of the missense mutation. (c and d) The Flag-tagged SFTPA1 and Myc-tagged SFTPA1 (c; WT or mutant [Mut]) or Flag-tagged SFTPA2 and Myc-tagged SFTPA1
(d; WT or Mut) cDNA was transfected into A549 cells. As a negative control, empty vector (EV) was transfected. 1 d after transfection, the cell pellets (cell) or
supernatant (sup) were immunoprecipitated with anti-Flag antibody, and the immunoprecipitates were blotted with an anti-Flag or Myc antibody. As a control,
total cell lysates were blotted with the anti-Flag or Myc antibody. WB, Western blot. Data shown are representative of five (c and d) independent experiments.
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Figure S2. Increased necroptosis in Sftpa1-KI mice and IPF patients. (a) The breeding scheme for the construction of Sftpa1-KI mice. The point mutation
was inserted at position 208 (Y208H). Southern blot analysis of genomic DNA fromWT and Sftpa1-KI mice. Genomic DNA frommice with homozygous (homo)
mutant allele or WT mice was digested with EcoRI and blotted with 39 and 59 probes. DT-A, diphtheria toxin fragment A; pA, polyadenylation signal; Pr,
promoter. (b) Survival analysis of WT (closed circles) or Sftpa1-KI mice (open circles; number of mice in each independent experiment is 20). **, P < 0.01 by log
rank test. Quantification of hydroxyproline contents in WT or Sftpa1-KI mice (number of mice in each independent experiment is seven) at the age of 35 wk.
Data are means ± SD. **, P < 0.01. (c) Virus titer in lung tissue was evaluated in WT (closed square) or Sftpa1-KI (red circle) mice infected with IAV. Results are
shown as means ± SD. (d) Survival analysis of WT (closed circles), Mlkl−/− (open circles), Sftpa1-KI (red squares), and Sftpa1-KI mice deficient inMlkl (Sfpta1-KI;
Mlkl−/− [closed squares]; number of mice in each independent experiment is 10). **, P < 0.01 by log rank test. The data are representative of three independent
experiments. Quantification of hydroxyproline contents inWT, Mlkl−/−, Sftpa1-KI, or Sftpa1-KI; Mlkl−/−mice (number of mice in each independent experiment is
10) 12 d after IAV infection. Data represent the means ± SD. **, P < 0.01. (e) Histological section was stained with anti–SP-C or pMLKL antibody in controls
(healthy part of lungs from three lung cancer patients) and three IPF patients without SFTPA1 mutation (#1, #2, and #3) and a patient with SFTPA1 mutation
(3P in Fig. S1 a). The scale bar indicates 20 μm. The ratios of pMLKL-positive cells/SP-C–positive cells in five distinct parts of images are shown. Data are
means ± SD. **, P < 0.01. Data shown are representative of five (b–f) independent experiments.
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Figure S3. The inhibition of JNK blocks pulmonary fibrosis. (a and b) The expression of phosphorylated eIF2α (a) or phosphorylated JNK (b) in WT or
Sftpa1-KI mice at the age of 35 wk was evaluated by Western blotting. Data are means ± SD. **, P < 0.01. (c) The expression of pJNK in WT or Sftpa1-KI mice at
the age of 30 wk was evaluated by immunohistochemistry. The pJNK-positive cells (average of the number of pJNK-positive cells in 10 independent fields in
right lung) was counted. Data are means ± SD. **, P < 0.01. The scale bar indicates 20 μm. (d)WT mice were injected with LPS (50 μg), and serum TNFα was
measured 3 h after LPS injection. The JNK inhibitor (30 mg/kg, s.c.) was administered 3 h before LPS injection. Data are means ± SD. **, P < 0.01. The data are
representative of two independent experiments. (e) This is an additional set of experiments for Fig. 3 b. Survival of 20-wk-old WT (red circles), WT infected
with adenovirus carrying Ripk3 (yellow squares), Sftpa1-KI mice infected with control virus (blue circles), Sftpa1-KI mice infected with control virus and treated
with a JNK inhibitor (brown triangles), or Sftpa1-KI mice infected with Ripk3-adenovirus and treated with a JNK inhibitor (green squares; number of mice in each
independent experiment is 10). *, P < 0.05; **, P < 0.01 by log rank test. Data shown are representative of five (a–d) independent experiments.
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